Association of serum occludin levels and perihematomal edema volumes in intracranial hemorrhage patients

IF 4.8 1区医学 Q1 NEUROSCIENCES

CNS Neuroscience & Therapeutics Pub Date : 2023-09-18 DOI:10.1111/cns.14450

Shuhua Yuan, Qingfeng Ma, Chengbei Hou, Yue Zhao, Ke Jian Liu, Xunming Ji, Zhifeng Qi

{"title":"Association of serum occludin levels and perihematomal edema volumes in intracranial hemorrhage patients","authors":"Shuhua Yuan, Qingfeng Ma, Chengbei Hou, Yue Zhao, Ke Jian Liu, Xunming Ji, Zhifeng Qi","doi":"10.1111/cns.14450","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Purpose</h3>\n \n <p>Perihematomal edema (PHE) is one of the severe secondary damages following intracranial hemorrhage (ICH). Studies showed that blood–brain barrier (BBB) injury contributes to the development of PHE. Previous studies showed that occludin protein is a potential biomarker of BBB injury. In the present study, we investigated whether the levels of serum occludin on admission are associated with PHE volumes in ICH patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This cross-sectional study included 90ICH patients and 32 healthy controls.The volumes of hematoma and PHE were assessed using non-contrast cranial CT within 30 min of admission. Blood samples were drawn on admission, and the levels of baseline serum occludin were detected using enzyme-linked immunosorbent assay. Partial correlation analysis and multiple linear regression analysis were performed to evaluate the association between serum occludin levels and PHE volumes in ICH patients.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The serum occludin levels in ICH patients were much higher than health controls (median 0.27 vs. 0.13 ng/mL, <i>p</i> < 0.001). At admission, 34 ICH patients (37.78%) had experienced a severe PHE (≥30 mL), and their serum occludin levels were higher compared to those with mild PHE (<30 mL) (0.78 vs. 0.21 ng/mL, <i>p</i> < 0.001). The area under the receiver operating characteristics curve (ROC) of serum occludin level in predicting severe PHE was 0.747 (95% confidence interval CI 0.644–0.832, <i>p</i> < 0.001). There was a significant positive correlation between serum occludin levels and PHE volumes (partial correlation <i>r</i> = 0.675, <i>p</i> < 0.001). Multiple linear regression analysis showed that serum occludin levels remained independently associated with the PHE volumes after adjusting other confounding factors.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The present study showed that serum occludin levels at admission were independently correlated with PHE volumes in ICH patients, which may provide a biomarker indicating PHE volume change.</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"30 3","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.14450","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.14450","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Purpose

Perihematomal edema (PHE) is one of the severe secondary damages following intracranial hemorrhage (ICH). Studies showed that blood–brain barrier (BBB) injury contributes to the development of PHE. Previous studies showed that occludin protein is a potential biomarker of BBB injury. In the present study, we investigated whether the levels of serum occludin on admission are associated with PHE volumes in ICH patients.

Methods

This cross-sectional study included 90ICH patients and 32 healthy controls.The volumes of hematoma and PHE were assessed using non-contrast cranial CT within 30 min of admission. Blood samples were drawn on admission, and the levels of baseline serum occludin were detected using enzyme-linked immunosorbent assay. Partial correlation analysis and multiple linear regression analysis were performed to evaluate the association between serum occludin levels and PHE volumes in ICH patients.

Results

The serum occludin levels in ICH patients were much higher than health controls (median 0.27 vs. 0.13 ng/mL, p < 0.001). At admission, 34 ICH patients (37.78%) had experienced a severe PHE (≥30 mL), and their serum occludin levels were higher compared to those with mild PHE (<30 mL) (0.78 vs. 0.21 ng/mL, p < 0.001). The area under the receiver operating characteristics curve (ROC) of serum occludin level in predicting severe PHE was 0.747 (95% confidence interval CI 0.644–0.832, p < 0.001). There was a significant positive correlation between serum occludin levels and PHE volumes (partial correlation r = 0.675, p < 0.001). Multiple linear regression analysis showed that serum occludin levels remained independently associated with the PHE volumes after adjusting other confounding factors.

Conclusion

The present study showed that serum occludin levels at admission were independently correlated with PHE volumes in ICH patients, which may provide a biomarker indicating PHE volume change.

Abstract Image

查看原文本刊更多论文

颅内出血患者血清闭塞素水平与血肿周围水肿体积的关系

背景和目的：颅周水肿（PHE）是颅内出血（ICH）后严重的继发性损伤之一。研究表明，血脑屏障（BBB）损伤是导致 PHE 发生的原因之一。以前的研究表明，闭塞蛋白是 BBB 损伤的潜在生物标志物。在本研究中，我们探讨了入院时血清闭塞素水平是否与 ICH 患者 PHE 容量相关：这项横断面研究包括 90 名 ICH 患者和 32 名健康对照者。入院时抽取血样，用酶联免疫吸附法检测血清闭塞素的基线水平。采用偏相关分析和多元线性回归分析评估 ICH 患者血清闭塞素水平与 PHE 容量之间的关系：结果：ICH 患者的血清闭塞素水平远高于健康对照组（中位数为 0.27 vs. 0.13 ng/mL，p 结论：ICH 患者的血清闭塞素水平与 PHE 容积之间存在显著的相关性：本研究表明，ICH 患者入院时的血清闭塞素水平与 PHE 体积独立相关，这可能是指示 PHE 体积变化的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS Neuroscience & Therapeutics 医学-神经科学

CiteScore

7.30

自引率

12.70%

发文量

240

审稿时长

2 months

期刊介绍： CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.